Erschienen in:
01.02.2015 | Image of the Month
68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient
verfasst von:
Christian Uprimny, Alexander Kroiss, Bernhard Nilica, Sabine Buxbaum, Clemens Decristoforo, Wolfgang Horninger, Irene J. Virgolini
Erschienen in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Ausgabe 2/2015
Einloggen, um Zugang zu erhalten
Excerpt
Recent reports suggest that
223Ra prolongs survival in prostate cancer patients [
1]. Bone scintigraphy is considered the gold standard in the assessment of osseous metastatic disease in prostate cancer [
2].
68Ga-labelled prostate-specific membrane antigen (PSMA) ligand is a novel, highly specific tracer for the detection of metastatic lesions of prostate cancer [
3]. …